Taiwan Advance Bio-Pharmaceutical Inc. (TPEX:4186)
Taiwan · Delayed Price · Currency is TWD 7.95
-0.07 (-0.87%)
Aug 26, 2026, 12:14 PM CST
TPEX:4186 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 347.94 | 363.98 | 353.49 | 315.43 | 276.9 | 239.59 |
Other Revenue | 0.61 | 0.81 | 0.68 | 0.56 | 41.34 | 3.77 |
| 348.54 | 364.79 | 354.17 | 315.98 | 318.24 | 243.36 | |
Revenue Growth | -6.27% | 3.00% | 12.09% | -0.71% | 30.77% | 3.31% |
Cost of Revenue | 134.88 | 130.72 | 110.21 | 117.53 | 125.66 | 118.57 |
Gross Profit | 213.66 | 234.07 | 243.97 | 198.46 | 192.58 | 124.79 |
Selling, General & Admin | 171.57 | 183.34 | 180.64 | 177.47 | 168.04 | 182.08 |
Research & Development | 12.97 | 13.34 | 18.49 | 16.72 | 16.14 | 45.51 |
Operating Expenses | 186.89 | 196.68 | 199.13 | 194.19 | 184.97 | 227.59 |
Operating Income | 26.77 | 37.39 | 44.84 | 4.27 | 7.61 | -102.79 |
Interest Expense | -7.16 | -6.52 | -7.42 | -7.3 | -6.13 | -7.43 |
Interest & Investment Income | 1.43 | 1.33 | 1.45 | 1.49 | 0.5 | 0.12 |
Currency Exchange Gain (Loss) | 0.14 | 0.14 | 1.2 | 1.35 | 4.1 | -0.56 |
Other Non Operating Income (Expenses) | -1.16 | -0.03 | 0.17 | 0.31 | -3.47 | 0.38 |
EBT Excluding Unusual Items | 20.02 | 32.31 | 40.23 | 0.12 | 2.6 | -110.29 |
Gain (Loss) on Sale of Investments | 2.43 | 2.43 | -14.69 | -1.23 | 2.58 | 2.06 |
Gain (Loss) on Sale of Assets | - | - | -0.03 | 0.38 | 0.01 | -0.03 |
Asset Writedown | - | - | - | -9.15 | -1.89 | -6.05 |
Other Unusual Items | -7.59 | -7.59 | -2.91 | -1.51 | 0.39 | -0.14 |
Pretax Income | 14.87 | 27.16 | 22.6 | -11.39 | 3.69 | -114.44 |
Income Tax Expense | -0.89 | -0.89 | -0.27 | -0.71 | 0.52 | 4.08 |
Net Income | 15.76 | 28.05 | 22.88 | -10.68 | 3.17 | -118.53 |
Net Income to Common | 15.76 | 28.05 | 22.88 | -10.68 | 3.17 | -118.53 |
Net Income Growth | -32.65% | 22.61% | - | - | - | - |
Shares Outstanding (Basic) | 86 | 90 | 90 | 90 | 90 | 90 |
Shares Outstanding (Diluted) | 86 | 90 | 90 | 90 | 90 | 90 |
Shares Change | -7.83% | - | - | - | - | 11.05% |
EPS (Basic) | 0.18 | 0.31 | 0.25 | -0.12 | 0.04 | -1.32 |
EPS (Diluted) | 0.18 | 0.31 | 0.25 | -0.12 | 0.04 | -1.32 |
EPS Growth | -26.43% | 24.00% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 18.88 | 19.77 | 4.37 | 0.67 | -27.87 | -63.28 |
Free Cash Flow Per Share | 0.22 | 0.22 | 0.05 | 0.01 | -0.31 | -0.70 |
Gross Margin | 61.30% | 64.17% | 68.88% | 62.80% | 60.51% | 51.28% |
Operating Margin | 7.68% | 10.25% | 12.66% | 1.35% | 2.39% | -42.24% |
Profit Margin | 4.52% | 7.69% | 6.46% | -3.38% | 1.00% | -48.70% |
Free Cash Flow Margin | 5.42% | 5.42% | 1.23% | 0.21% | -8.76% | -26.00% |
EBITDA | 40.79 | 51.69 | 59.91 | 24.95 | 30.97 | -77.72 |
EBITDA Margin | 11.70% | 14.17% | 16.91% | 7.90% | 9.73% | -31.94% |
D&A For EBITDA | 14.02 | 14.3 | 15.07 | 20.69 | 23.36 | 25.07 |
EBIT | 26.77 | 37.39 | 44.84 | 4.27 | 7.61 | -102.79 |
EBIT Margin | 7.68% | 10.25% | 12.66% | 1.35% | 2.39% | -42.24% |
Effective Tax Rate | - | - | - | - | 13.98% | - |
Revenue as Reported | 348.54 | 364.79 | 354.17 | 315.98 | 318.24 | 243.36 |
Advertising Expenses | - | 16.12 | - | - | - | - |